University of Minnesota. Driven to Discover.
The $275 million deal will make the company the second leading player in the $4 billion global flu vaccine market.
Study suggests the high-dose flu vaccine gives seniors significantly better protection than standard-dose vaccines.
Producers recently began shipping doses of a US supply that has more quadrivalent products in the mix this year.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
Become an underwriter»
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.